Charlie Strange to Adrenergic beta-2 Receptor Agonists
This is a "connection" page, showing publications Charlie Strange has written about Adrenergic beta-2 Receptor Agonists.
Connection Strength
3.003
-
Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:1377-1388.
Score: 0.639
-
Evaluating fluticasone furoate + vilanterol for the treatment of chronic obstructive pulmonary disease (COPD). Expert Opin Pharmacother. 2019 Jun; 20(9):1075-1085.
Score: 0.630
-
A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD. Expert Opin Pharmacother. 2017 Dec; 18(17):1833-1843.
Score: 0.571
-
Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy. Int J Chron Obstruct Pulmon Dis. 2017; 12:135-140.
Score: 0.538
-
Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015 Feb; 16(3):427-34.
Score: 0.471
-
Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments. Int J Chron Obstruct Pulmon Dis. 2015; 10:2055-66.
Score: 0.123
-
Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment. J Manag Care Spec Pharm. 2016 Mar; 22(3):293-304.
Score: 0.032